Navigation Links
AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use
Date:10/19/2011

NEW YORK, Oct. 19, 2011 /PRNewswire/ -- It is well known that ophthalmologists around the world often prescribe Avastin (bevacizumab) off-label for wet age-related macular degeneration (AMD) over the approved treatment Lucentis (ranibizumabintravitreal) due to cost and the belief that the two have similar efficacy.

AMD Alliance International (AMDAI) is calling for ophthalmologists to stop this practice in light of a concerning surge in eye infections over the past month in patients being treated with repackaged Avastin.(i) The US Food and Drug Administration (FDA) has issued a formal warning to health care professionals about Avastin's risk for infection(ii). The US Department of Veterans Affairs has also stopped using Avastin in wet AMD patients.(iii) The Alliance urges other healthcare providers to follow suit.    

"AMDAI always advocates that evidence-based medicine and patient safety should set as the preferred treatment protocol for wet AMD, not cost," said Narinder Sharma BSc. Hons., MBA, PGDL, CEO of AMDAI. "In this case, the approved treatment based on safety and efficacy data is Lucentis. Unfortunately, we have effectively traded patient safety for money. That is just not acceptable."

Furthermore, since Avastin is not approved for ocular use, there is no pharma covigilance program for Avastin in ocular use, therefore side effects and safety issues are not monitored or reported.

AMDAI is also strongly recommending the following actions:

  • Patients and caregivers should practice increased vigilance and informed consent:
    • Patients should ask their health care providers about and fully acknowledge all possible risks associated with Avastin.
    • Patients should work with their health care providers to gain access to approved treatments whenever possible.
  • Physicians should stop prescribing Avastin as the first-line treatment for wet AMD, as advised by the US Department of Veterans Affairs(iii), especially if Lucentis is available to their patients through insurance coverage.  
  • Manufacturers of licensed therapies, Medicare and other health insurers should work together to increase access to safe and approved treatments.  

"AMD is a debilitating disease and without treatment can lead to blindness," said Alan Cruess, MD, Chairman, Department of Ophthalmology and Visual Sciences, Dalhousie University and Chairman of AMDAI's Scientific Advisory Panel. "Patients diagnosed with AMD are going through a lot of confusion and uncertainty. They need access to safe and effective medicines and shouldn't have to worry about sacrificing safety when it comes to treatment."

AMDAI strongly encourages doctors, patients with wet AMD and their caregivers to fully understand the issue before making a treatment decision. A more detailed summary of known risks and cost issues associated with Avastin and Lucentis is available at amdalliance.org.

About AMDAI

AMD Alliance International strives to bring knowledge, help and hope to individuals and families around the world affected by AMD. Our mission is accomplished through:

  • Generating awareness and understanding of age-related macular degeneration;
  • Promoting the importance of education, early detection, knowledge of treatment and rehabilitation options; and
  • Preserving vision and improving the quality of life of individuals affected by age-related macular degeneration.  

(i) Consists of aggregate data from the following countries:


(ii) FDA Alerts Health Care Professionals of Infection Risk from Repackaged AvastinIntravitreal Injections. Available at http://www.fda.gov/Drugs/DrugSafety/ucm270296.htm

(iii) US Department of Veterans Affairs public statement.


'/>"/>
SOURCE AMDAI
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OXIS International Assumes Control and Exploitation Rights to Key L-Ergothioneine Patent Filing Representing a Major Market Opportunity
2. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... New York , May 23, 2016 ... market report titled, " Exocrine Pancreatic Insufficiency Market - ... 2013 - 2023 ." According to the report, the ... a CAGR of 8.3% from 2015 to 2023 to ... insufficiency (EPI) is a condition characterized by the deficiency ...
Breaking Medicine Technology:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... "FCPX LUT ... quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/25/2016)... ... May 25, 2016 , ... HealthPostures ... will join America's leading engineers at the American Society of Safety Engineers Conference ... Congress Center. , Engineers, speakers and exhibitors from more than 40 countries ...
(Date:5/24/2016)... ... May 24, 2016 , ... BTC Media, a ... event, Distributed: Health, to be held in Nashville, Tennessee on September 7, 2016. ... 24-hour Hackathon preceding the event will host teams from around the world, competing ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... a new corporate identity and website at its “Transforming Outcomes” User Conference in ... marketing enhancements reflect i2i’s ongoing success to set the market standard for meaningful ...
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... ... for the Surgery Center at Sentara Northern Virginia Medical Center located in Woodbridge, ... of the hospital’s surgical services into a single site. , The new 2 ...
Breaking Medicine News(10 mins):